The role of the PET scan in the management of sarcoidosis

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 5, 2013, Pages 538-544

  Mostard, Rémy L M ^a   Van Kroonenburgh, Marinus J P G ^b   Drent, Marjolein ^c  

^a Zuyderland Medical Centre   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Inflammatory activity; Organ involvement; PET; Prognosis; Sarcoidosis

Indexed keywords

DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY DISEASE; LUNG FIBROSIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; REVIEW; SARCOIDOSIS; SYMPTOM;

BIOPSY; DISEASE MANAGEMENT; FIBROSIS; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SARCOIDOSIS, PULMONARY; SENSITIVITY AND SPECIFICITY;

EID: 84881669167     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328363ed0d     Document Type: Review

References (46)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736-755
2. Iannuzzi MC, Fontana Jr. Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305:391-399
3. Keijsers RG, Verzijlbergen FJ, Oyen WJ, et al. 18F-FDG PET, genotypecorrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009; 36:1131-1137
4. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132:1949-1953
5. Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: Review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35:1537-1543
6. Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: Sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging 2011; 55:66-71
7. Keijsers RG, Van den Heuvel DAF, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J 2013; 41:743-751
8. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006; 47:1571-1576
9. Mostard RL, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by 18F FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011; 105:1917-1924
10. Mostard RL, Verschakelen JA, van Kroonenburgh MJ, et al. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med 2013; 107:439-447
11. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 2012; 53:1543-1549
12. Ziegenhagen MW, Rothe ME, Schlaak M, Muller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003; 21:407-413
13. Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38:628-634
14. De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:127-136
15. Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med 2010; 31:501-518
16. Teirstein AT, Morgenthau AS. 'End-stage' pulmonary fibrosis in sarcoidosis. Mt Sinai J Med 2009; 76:30-36
17. Grutters JC, Fellrath JM, Mulder L, et al. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: A clinical evaluation. Chest 2003; 124:186-195
18. Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156:1586-1592
19. Prasse A, Katic C, Germann M, et al. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 2008; 177:330-336
20. Muller-Quernheim J. Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15:22-37
21. Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49:1510-1517
22. Keir G, Wells AU. Assessing pulmonary disease and response to therapy; which test? Semin Respir Crit Care Med 2010; 31:409-418
23. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183:573-581
24. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132:207-213
25. Drent M, De Vries J, Lenters M, et al. Sarcoidosis: Assessment of disease severity using HRCT. Eur Radiol 2003; 13:2462-2471
26. Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis; CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 2000; 174:1751-1757
27. Brauner MW, Lenoir S, Grenier P, et al. Pulmonary sarcoidosis: CT assessment of lesion reversibility. Radiology 1992; 182:349-354
28. Murdoch J, Muller NL. Pulmonary sarcoidosis: Changes on follow-up CT examination. AJR Am J Roentgenol 1992; 159:473-477
29. Oberstein A, von Zitzewitz H, Schweden F, Muller-Quernheim J. Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:65-72
30. Groves AM, Win T, Screaton NJ, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: Implications from initial experience with 18F-FDG PET/CT. J Nucl Med 2009; 50:538-545
31. Umeda Y, Demura Y, Ishizaki T, et al. Dual-Time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging 2009; 36:1121-1130
32. Ortiz PA,Haspel HC.Differential control of the functional cell surface expression and content of hexose transporter GLUT-1 by glucose and glucose metabolism in murine fibroblasts. Biochem J 1993; 295 (Pt 1): 67-72
33. Consensus conference: Activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, 8-11 September 1993. Eur Respir J 1994; 7:624-627
34. Mostard RL, Kuijk SM, Verschakelen JA, et al. A predictive tool for an effective use of 18F-FDG PET in assessing activity of sarcoidosis. BMC Pulm Med 2012; 12:57
35. Keijsers RG, Grutters JC, van Velzen-Blad H, et al. (18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. Eur J Nucl Med Mol Imaging 2010; 37:1181-1188
36. Drent M, Jacobs JA, de Vries J, et al. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 1999; 13:1338-1344
37. Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28:123-129
38. Zisman DA, Shorr AF, Lynch JP 3rd. Sarcoidosis involving the musculoskeletal system. Semin Respir Crit Care Med 2002; 23:555-570
39. Mostard RL, Prompers L, Weijers RE, et al. F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med 2012; 37:21-25
40. Tutt AN, Plunkett TA, Barrington SF, Leslie MD. The role of positron emission tomography in the management of colorectal cancer. Colorectal Dis 2004; 6:2-9
41. Baughman RP, Lower EE. Who dies from sarcoidosis and why? Am J Respir Crit Care Med 2011; 183:1446-1447
42. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53:241-248
43. McArdle BA, Leung E,Ohira H, et al. The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis andmanagement in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol 2013; 20:297-306
44. Soussan M, Brillet PY, Nunes H, et al. Clinical value of a high-fat and lowcarbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013; 20:120-127
45. Keijsers RG, Verzijlbergen JF, van Diepen DM, et al. 18F-FDG PET in sarcoidosis: An observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25:143-149
46. Milman N, Graudal N, Loft A, Mortensen J, et al. Effect of the TNFalpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: A prospective observational study using FDG-PET. Clin Respir J 2012; 6:238-247